Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer.
chemotherapy
head and neck neoplasms
morbidity
surgery
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
15
05
2020
revised:
16
06
2020
accepted:
20
06
2020
pubmed:
25
7
2020
medline:
12
6
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
Neoadjuvant chemotherapy (NAC) has been used in patients with advanced head and neck cancers (HNCs) with the intent of downstaging tumors and suppressing distant metastases. However, to the authors' knowledge, the perioperative impact of NAC has not been systematically explored in patients with HNC. The objective of the current study was to compare perioperative outcomes with surgery upfront compared with patients treated with NAC. Between March 1, 2016, and March 31, 2019, patients undergoing surgery for HNC with flap reconstruction at The University of Texas MD Anderson Cancer Center in Houston were included. Data were extracted from the prospectively maintained National Surgical Quality Improvement Program database. Postoperative complications, return to operating room, and readmission rates were compared. Univariate and multivariate analyses of length of stay and overall and wound complications were performed. A total of 834 patients were analyzed, 687 of whom (82.4%) underwent surgery upfront and 147 of whom (17.6%) received NAC. A total of 631 cases (75.7%) involved the upper aerodigestive tract whereas 203 cases (24.3%) were cutaneous. A total of 317 patients (38.0%) had recurrent disease. The NAC group was younger (P < .001) and had less hypertension (P = .011), but had more advanced clinical stage tumors (P < .001) and surgeries with multiple flap reconstruction (P = .007). Patient groups did not differ with regard to wound complications (P = .47), return to operating room (P = .31), or readmission rates (P = .49). The NAC group received more blood transfusions (P < .001) but was found to have a lower risk of overall complications on multivariate analysis (odds ratio, 0.50; 95% CI, 0.30-0.83). The overall complication rate was unchanged with surgery performed ≤21 days after the last chemotherapy cycle. Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.
Sections du résumé
BACKGROUND
Neoadjuvant chemotherapy (NAC) has been used in patients with advanced head and neck cancers (HNCs) with the intent of downstaging tumors and suppressing distant metastases. However, to the authors' knowledge, the perioperative impact of NAC has not been systematically explored in patients with HNC. The objective of the current study was to compare perioperative outcomes with surgery upfront compared with patients treated with NAC.
METHODS
Between March 1, 2016, and March 31, 2019, patients undergoing surgery for HNC with flap reconstruction at The University of Texas MD Anderson Cancer Center in Houston were included. Data were extracted from the prospectively maintained National Surgical Quality Improvement Program database. Postoperative complications, return to operating room, and readmission rates were compared. Univariate and multivariate analyses of length of stay and overall and wound complications were performed.
RESULTS
A total of 834 patients were analyzed, 687 of whom (82.4%) underwent surgery upfront and 147 of whom (17.6%) received NAC. A total of 631 cases (75.7%) involved the upper aerodigestive tract whereas 203 cases (24.3%) were cutaneous. A total of 317 patients (38.0%) had recurrent disease. The NAC group was younger (P < .001) and had less hypertension (P = .011), but had more advanced clinical stage tumors (P < .001) and surgeries with multiple flap reconstruction (P = .007). Patient groups did not differ with regard to wound complications (P = .47), return to operating room (P = .31), or readmission rates (P = .49). The NAC group received more blood transfusions (P < .001) but was found to have a lower risk of overall complications on multivariate analysis (odds ratio, 0.50; 95% CI, 0.30-0.83). The overall complication rate was unchanged with surgery performed ≤21 days after the last chemotherapy cycle.
CONCLUSIONS
Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4304-4314Informations de copyright
© 2020 American Cancer Society.
Références
Dauzier E, Lacas B, Blanchard P, et al. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: a subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncol. 2019;95:106-114.
Pignon JP, Le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
Spector ME, Rosko AJ, Swiecicki PL, Chad Brenner J, Birkeland AC. From VA larynx to the future of chemoselection: defining the role of induction chemotherapy in larynx cancer. Oral Oncol. 2018;86:200-205.
Busch CJ, Tribius S, Schafhausen P, Knecht R. The current role of systemic chemotherapy in the primary treatment of head and neck cancer. Cancer Treat Rev. 2015;41:217-221.
Zhong L, Zhang C, Ren G, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and flourouracil followed by surgery versus upfront surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744-751.
Bossi P, Lo Vullo S, Guzzo M, et al. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 2014;25:462-466.
Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell carcinoma: a randomized controlled trial. J Clin Oncol. 2003;21:327-333.
Shamberger RC, Devereux DF, Brennan MF. The effect of chemotherapeutic agents on wound healing. Int Adv Surg Oncol. 1981;4:15-58.
Adamson K, Chavez-MacGregor M, Caudle A, et al. Neoadjuvant chemotherapy does not increase complications in oncoplastic breast-conserving surgery. Ann Surg Oncol. 2019;26:2730-2737.
Johnson DC, Nielsen ME, Matthews J, et al. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU Int. 2014;114:221-228.
Lewis CM, Aloia TA, Shi W, et al. Development and feasibility of a specialty-specific National Surgical Quality Improvement Program (NSQIP): the Head and Neck-Reconstructive Surgery NSQIP. JAMA Otolaryngol Head Neck Surg. 2016;142:321-327.
American College of Surgeons. User Guide for the 2014 ACS NSQIP Participant Use Data File (PUF). Accessed June 16, 2020. https://www.facs.org/-/media/files/qualityprograms/nsqip/nsqip_puf_userguide_2014.ashx
Pecorelli N, Pagnanelli M, Cinelli L, et al. Postoperative outcomes and functional recovery after preoperative combination chemotherapy for pancreatic cancer: a propensity score-matched study. Front Oncol. 2019;9:1299.
Subramaniam S, Aalberg JJ, Soriano RP, Divino CM. New 5-factor modified frailty index using American College of Surgeons NSQIP data. J Am Coll Surg. 2018;226:173-181.e8.
Crippen MM, Patel N, Filimonov A, et al. Association of smoking tobacco with complications in head and neck microvascular reconstructive surgery. JAMA Facial Plast Surg. 2019;21:20-26.
Le Nobel GJ, Higgins KM, Enepekides DJ. Predictors of complications of free flap reconstruction in head and neck surgery: analysis of 304 free flap reconstruction procedures. Laryngoscope. 2012;122:1014-1019.
Neiman CL, Pitman KT, Tufaro AP, Eisele DW, Frick KD, Gourin CG. The effect of frailty on short-term outcomes after head and neck cancer surgery. Laryngoscope. 2018;128:102-110.
Neiman CL, Stewart MC, Eisele DW, Provonost PJ, Gourin CG. Frailty, hospital volume, and failure to rescue after head and neck cancer surgery. Laryngoscope. 2018;128:1365-1370.
Liu JH, Zingmond DS, McGory ML, et al. Disparities in the utilization of high-volume hospitals for complex surgery. JAMA. 2006;296:1973-1980.
Andrades P, Bohannon IA, Baranano CF, Wax MK, Rosenthal E. Indications and outcomes of double free flaps in head and neck reconstruction. Microsurgery. 2009;29:171-177.
Santoro L, Tagliabue M, Massaro MA, et al. Algorithm to predict postoperative complications in oropharyngeal and oral cavity carcinoma. Head Neck. 2015;37:548-556.
BuSaba NY, Schaumberg DA. Predictors of prolonged length of stay after major elective head and neck surgery. Laryngoscope. 2007;117:1756-1763.
Penel N, Lefebvre D, Fournier C, Sarini J, Kara A, Lefebvre JL. Risk factors for wound infection in head and neck cancer surgery: a prospective study. Head Neck. 2001;23:447-455.
Peters TT, van Dijk BA, Roodenburg JL, van der Laan BF, Halmos GB. Relation between age, comorbidity and complications in patients undergoing major surgery for head and neck cancer. Ann Surg Oncol. 2014;21:963-970.
Philips R, Seim N, Marcinow A, et al. The high stakes of head and neck surgery following radiation and chemotherapy-an assessment of complications and survival. Oral Oncol. 2019;94:14-20.
Hackett NJ, De Oliveira GS, Jain UK, Kim JY. ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg. 2015;18:184-190.
Gronkjaer M, Eliasen M, Skov-Ettrup LS, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. Ann Surg. 2014;259:52-71.
Turan A, Mascha EJ, Roberman D, et al. Smoking and perioperative outcomes. Anesthesiology. 2011;114:837-846.
Brady JS, Crippen MM, Filimonov A, Eloy JA, Baredes S, Park RCW. Laryngectomy and smoking: an analysis of postoperative risk. Laryngoscope. 2017;127:2302-2309.
Choi S, Schwartz DL, Farwell DG, Austin-Seymour M, Futran N. Radiation therapy does not impact local complication rates after free flap reconstruction for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:1308-1312.
Lin S, Dutra J, Keni J, Dumanian GA, Fine N, Pelzer H. Preoperative radiation therapy and its effects on outcomes in microsurgical head and neck reconstruction. Otolaryngol Head Neck Surg. 2005;132:845-848.
Graboyes EM, Kompelli AR, Neskey DM, et al. Association of treatment delays with survival for patients with head and neck cancer-a systemic review. JAMA Otolaryngol Head Neck Surg. 2019;145:166-177.
Sutton TL, Johnson N, Schlitt A, Gardiner SK, Garreau JR. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates. Am J Surg. 2020;219:741-745.
Suleman K, Almalik O, Mushtag A, et al. Does the timing of surgery after neoadjuvant therapy in breast cancer patients affect the outcome? Oncology. 2020;98:168-173.
Liu SA, Wong YK, Wang CP, et al. Surgical site infection after preoperative neoadjuvant chemotherapy in patients with locally advanced oral squamous cell carcinoma. Head Neck. 2011;33:954-958.
Joshi P, Joshi A, Prabhash K, Noronha V, Chaturvedi P. Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone. Indian J Med Paediatr Oncol. 2015;36:249-254.